DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hemangiopericytoma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHemangiopericytoma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hemangiopericytoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
catenin beta 1 (CTNNB1) — CTNNB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet prodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8Z10 · 2.35 Å · ligand PROLINE (PRO). Experimental structure, not a prediction.
What the evidence adds up to
In a 1978 review of 39 chemotherapy trials in 16 patients with metastatic hemangiopericytoma at Memorial Sloan Kettering, plus 33 trials from the literature, adriamycin (doxorubicin) alone or in combination produced complete and partial remission in 50% of cases. Other drugs with some reported activity included vincristine, cyclophosphamide, actinomycin, methotrexate and DTIC. The authors concluded that malignant hemangiopericytoma should be considered chemotherapeutically responsive. A 1974 report from the National Cancer Institute of Milan on 11 cases noted that surgical excision played a very important role in management and that palliative results had recently been obtained with chemotherapy, but gave no response rates or survival numbers.
A 2020 case report described a 29-year-old pineoblastoma patient who developed an intracranial hemangiopericytoma at a different location four years after successful surgical excision and adjuvant radiotherapy for the original tumour. The authors concluded that hemangiopericytoma emergence can be seen after radiotherapy. A 2024 case report described a patient with disseminated hemangiopericytoma treated with radiation alone, emphasising that careful use of different radiotherapy techniques in tandem allowed long survival and preserved quality of life, but this is a single case and no survival duration or tumour response measurements were given.
The evidence base remains limited to small retrospective series and single case reports. No prospective trial has defined optimal chemotherapy, radiotherapy dose-fractionation, or sequence of modalities. The 1978 response rate of 50% to adriamycin-based regimens has not been replicated in a modern, larger cohort. What is missing is a multi-centre registry or randomised trial that stratifies patients by histological grade, mutational profile, and extent of disease, and that measures progression-free survival and quality of life with standardised criteria. Funding for such a trial has not been reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 1978 · 154 citations · open access
Chemotherapy of malignant hemangiopericytoma
AbstractThirty-nine chemotherapy trials in 16 patients with metastatic hemangiopericytoma treated at MSKCC and 33 trials from the literature are reviewed. Adriamycin, alone or in combination drug regimens, is the most effective agent, producing complete and partial remission in 50% of cases. Other drugs which show some activity include vincristine, cyclophosphamide, actinomycin, methotrexate and DTIC. The available data indicate malignant hemangiopericytoma should be considered chemotherapeutically responsive tumors.
Report of 11 Cases of Hemangiopericytoma and Review of the Most Recent Literature.
AbstractThe main features of the hemangiopericytoma: its ubiquity, the different grades of malignancy, the lack of correlation between clinical and histological features are discussed in the light of the literature and the experience gained at the National Cancer Institute of Milan. Surgical excision plays a very important role in the management of this tumor. The palliative results recently obtained with chemotherapy are set forth.
British Journal of Neurosurgery · 2020 · 0 citations
Intracranial hemangiopericytoma after radiation treatment: first case in the literature
AbstractBACKGROUND: Radiation exposure is a known risk factor for meningioma but there are no data regarding hemangiopericytoma and radiation exposure. CASE DESCRIPTION: We report a 29-year-old pineoblastoma patient diagnosed with a hemangiopericytoma at a different location, after a successful surgical excision and adjuvant radiotherapy for the original tumor 4-year prior. CONCLUSION: Hemangiopericytoma emergence can be seen after radiotherapy.
Exclusive Real World Evidence Journal · 2024 · 0 citations
Long and Meaningful Survival of a Case with Disseminated Hemangiopericytoma - Treated with Radiation Alone
AbstractHemangiopericytomas are tumours arising from the pericytes of Zimmerman. They arise in the central nervous system and have a locally recurrent behaviour with occasional distant metastases too. This case highlights the careful and judicious use of different radiotherapy techniques used in tandem to ensure a long survival for a patient. Emphasis is made on the quality of life as he was able to function to his maximum till the end.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
